Daiichi Sankyo (OTCMKTS:DSNKY) Trading Up 0.6% - Time to Buy?

Key Points

• Daiichi Sankyo's stock price increased by 0.6%, reaching a last traded price of $24.78, despite a 40% drop in trading volume compared to its average.
• Nomura Securities upgraded Daiichi Sankyo to a "strong-buy" rating, signaling positive growth expectations from analysts.
• The company has a market capitalization of $46.94 billion and maintains solid financial ratios, including a current ratio of 2.53.

Daiichi Sankyo Co., Ltd. - Sponsored ADR (OTCMKTS:DSNKY - Get Free Report)'s stock price was up 0.6% during trading on Monday . The company traded as high as $24.79 and last traded at $24.78. Approximately 139,943 shares changed hands during mid-day trading, a decline of 40% from the average daily volume of 231,911 shares. The stock had previously closed at $24.63.

Wall Street Analysts Forecast Growth

Separately, Nomura Securities upgraded shares of Daiichi Sankyo to a "strong-buy" rating in a research report on Friday, June 6th.

Daiichi Sankyo Trading Up 0.6%

The company's fifty day simple moving average is $24.06 and its two-hundred day simple moving average is $24.38. The company has a quick ratio of 1.85, a current ratio of 2.53 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $46.94 billion and a price-to-earnings ratio of 24.06.

About Daiichi Sankyo

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.